Display Settings:

Format
Items per page

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 29

1.

Epididymitis

Inflammation of the EPIDIDYMIS. Its clinical features include enlarged epididymis, a swollen SCROTUM; PAIN; PYURIA; and FEVER. It is usually related to infections in the URINARY TRACT, which likely spread to the EPIDIDYMIS through either the VAS DEFERENS or the lymphatics of the SPERMATIC CORD. [from MeSH]

MedGen UID:
4986
Concept ID:
C0014534
Disease or Syndrome
2.

alpha 1-Antitrypsin

Alpha-1-antitrypsin (418 aa, ~47 kDa) is encoded by the human SERPINA1 gene. This protein plays a role in regulation of proteolysis. [from NCI]

MedGen UID:
215
Concept ID:
C0002191
Pharmacologic Substance
3.

Epididymitis

The presence of `inflammation` (MPATH:212) of the `epididymis` (FMA:18255). [from HPO]

MedGen UID:
504311
Concept ID:
CN000032
Finding
4.

Mild

The second level of severity in an ordered list based on a five-level scale of minimal, mild, moderate, marked, and severe. [from NCI]

MedGen UID:
422477
Concept ID:
C2945599
5.

PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY

MedGen UID:
349287
Concept ID:
C1861457
Disease or Syndrome
6.

Discontinued

To stop or end, permanently or temporarily. [from NCI]

MedGen UID:
303183
Concept ID:
C1444662
Finding
7.

Serious Adverse Event

Any expected or unexpected adverse event, related or unrelated to the intervention, occurring at any agent dose, any phase of product or procedure testing, that results in any of the following outcomes: death, a life-threatening adverse event, requires inpatient hospitalization (not required as part of the treatment) or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or cancer, or a congenital anomaly or birth defect. Important medical events that may not result in the listed outcomes may be considered as serious when, based upon appropriate medical judgment, they represent significant hazards or potentially serious harm to the research subject or others and may require medical intervention to prevent one of the outcomes listed in this definition. [from NCI]

MedGen UID:
276798
Concept ID:
C1519255
Finding
8.

Adverse event

Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. NOTE: For further information, see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. "[Modified from ICH E2A]" Synonyms: side effect, adverse experience. See also serious adverse event, serious adverse experience. (CDISC glossary) [from NCI]

MedGen UID:
209094
Concept ID:
C0877248
Pathologic Function
9.

Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily. [from NCI]

MedGen UID:
167049
Concept ID:
C0795657
10.

Context

The universe of discourse that surrounds a language unit and helps to determine its interpretation. [from NCI]

MedGen UID:
105274
Concept ID:
C0449255
Finding
11.

Unrelated

Not connected or associated e.g. by kinship. [from NCI]

MedGen UID:
99027
Concept ID:
C0445356
Finding
12.

Alpha-1-antitrypsin deficiency

Alpha-1 antitrypsin deficiency (AATD) is characterized by an increased risk for: chronic obstructive pulmonary disease (i.e., emphysema, persistent airflow obstruction, and/or chronic bronchitis) in adults; liver disease in children and adults; panniculitis ; and c-ANCA positive vasculitis. Emphysema, sometimes with associated bronchiectasis, is the most common manifestation of AATD. Smoking is the major factor influencing the course of chronic obstructive pulmonary disease (COPD). The onset of respiratory disease in smokers with AATD is characteristically between ages 40 and 50 years; in non-smokers, the onset can be delayed to the sixth decade, and some non-smokers never develop COPD. Non-smokers may have a normal life span. Although reported, emphysema in children with AATD is extremely rare. AATD-associated liver disease, which is present in only a small portion of affected children, manifests as obstructive jaundice and increased serum aminotransferase levels in the early days and months of life. The incidence of liver disease increases with age. Liver disease in adults (manifesting as cirrhosis and fibrosis) may occur in the absence of a history of neonatal or childhood liver disease. The risk for hepatocellular carcinoma (HCC) is increased in individuals with AATD. [from GeneReviews]

MedGen UID:
67461
Concept ID:
C0221757
Disease or Syndrome
13.

Zemaira

MedGen UID:
233096
Concept ID:
C1330611
Pharmacologic Substance
14.

MedGen UID:
196164
Concept ID:
C0701947
15.

Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero. [from MeSH]

MedGen UID:
181981
Concept ID:
C0950123
16.

Injectable Drugs

A drug or medicine that can be injected [from CHV]

MedGen UID:
88572
Concept ID:
C0086466
Pharmacologic Substance
17.

Serpin

Irreversible serine proteinase inhibitors that exert their action on peptidases. Serpins can be localized inside, or outside of the cell, and are found in all groups of organisms with the exception of fungi. In human plasma, serpins represent approximately 2% of the total protein present. [from NCI]

MedGen UID:
48634
Concept ID:
C0036764
Pharmacologic Substance
18.

Immunoglobulins

there are two types of polypeptide chains responsible for the biological and immunological properties of the different immunoglobulins, the heavy chain and the light chain; they are linked by covalent and non-covalent forces to give a four-chain Y-shaped structure based on pairs of identical heavy and light chains; each chain consists of a variable region and a constant region which are coded for by different genes; some immunoglobulin classes occur as polymers of this basic monomer. [from CRISP]

MedGen UID:
43841
Concept ID:
C0021027
Pharmacologic Substance
19.

Subcutaneous emphysema

Presence of air or gas in the subcutaneous tissues of the body. [from MeSH]

MedGen UID:
21365
Concept ID:
C0038536
Pathologic Function
20.

Respiratory Tract Diseases

MedGen UID:
19750
Concept ID:
C0035242
Disease or Syndrome

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...